Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 9/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21485583 | 0.90 | CRHR1 (0.46) | CNR1MCHR1DRD4CRHR1CRHR2 | |
| SCHEMBL21482145 | 0.90 | CRHR1 (0.46) | CNR1MCHR1DRD4CRHR1CRHR2 | |
| SCHEMBL21506716 | 0.89 | CNR1 (0.43) | CNR1MCHR1DRD4CRHR1CNR2 | |
| SCHEMBL21506722 | 0.89 | CNR2 (0.39) | CNR1MCHR1DRD4CNR2IDH1 | |
| SCHEMBL26608128 | 0.88 | CNR1 (0.49) | CNR1MCHR1DRD4CNR2 | |
| SCHEMBL22927021 | 0.87 | CRHR1 (0.39) | CNR1MCHR1CRHR1CRHR2CNR2 | |
| SCHEMBL24784568 | 0.86 | CRHR1 (0.41) | MCHR1CRHR1CRHR2IDH1 | |
| SCHEMBL24784527 | 0.86 | CRHR1 (0.47) | CNR1MCHR1CRHR1CRHR2CNR2 | |
| SCHEMBL21481977 | 0.86 | CNR1 (0.43) | CNR1CRHR1CRHR2CNR2 | |
| SCHEMBL24784544 | 0.85 | CRHR1 (0.45) | CNR1MCHR1CRHR1CRHR2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | CNR1 6/4885MCHR1 1023/4885DRD4 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.